secwatch.observer — SEC 8-K summary
======================================

Issuer:     TITAN PHARMACEUTICALS INC (—)
CIK:        0000910267
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001829126-24-002106
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Titan Pharma restates Q3 2023 financials; $406K misclassified as operating expense
--------------------------------------------------------------------------------

- Board concluded Q3 2023 financials should no longer be relied upon due to material error.
- $406,000 incorrectly classified as issuance cost for Series AA Preferred Stock; should be operating expense.
- Restated financials for three and nine months ended Sep 30, 2023 will be included in 2023 10-K.
- Company expects to report at least one material weakness in internal controls due to the error.
- Error does not change cash position; discussions with auditor WithumSmith+Brown completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/910267/000182912624002106/0001829126-24-002106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/910267/000182912624002106/titanpharma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-24-002106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer